Further, studies have revealed that FTO expression is closely correlated with low differentiation, peritumoral lymphovascular invasion, lymph node metastasis and is positively correlated with TNM stage in HCC, GC, HER2-positive breast cancer and bladder cancer, which makes FTO a possible biomarker for diagnostic and prognostic purposes (Cui et al., 2020; Tao et al., 2021; Xu et al., 2017; Xu et al., 2020b). The gene discussed is FTO; the disease is hepatocellular carcinoma.